Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy (Q43478016)

23 November 2017

Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy (English)

1 reference

23 November 2017

1 reference

M Geier

1

1 reference

23 November 2017

S T Astner

2

1 reference

23 November 2017

M N Duma

3

1 reference

23 November 2017

V Jacob

4

1 reference

23 November 2017

C Nieder

5

1 reference

23 November 2017

J Putzhammer

6

1 reference

23 November 2017

C Winkler

7

1 reference

23 November 2017

M Molls

8

1 reference

23 November 2017

H Geinitz

9

1 reference

23 November 2017

26 February 2012

1 reference

Strahlentherapie und Onkologie

23 November 2017

1 reference

23 November 2017

188

1 reference

23 November 2017

410-416

1 reference

23 November 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00066-012-0081-8

23 November 2017

0 references

cites work

Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

What hypofractionated protocols should be tested for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Longitudinal study of intestinal symptoms and fecal continence in patients with conformal radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Prostate image-guided radiotherapy by megavolt cone-beam CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0081-8

Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer

21 January 2018

1 reference

12 December 2020

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

1 reference

12 December 2020

Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer

1 reference

12 December 2020

A Study to Quantify the Effectiveness of Daily Endorectal Balloon for Prostate Intrafraction Motion Management

1 reference

12 December 2020

Prediction of radial distance of extraprostatic extension from pretherapy factors

1 reference

12 December 2020

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

12 December 2020

Tomotherapy for prostate adenocarcinoma: a report on acute toxicity

1 reference

12 December 2020

Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer

1 reference

12 December 2020

Hypofractionation for prostate cancer radiotherapy—what are the issues?

1 reference

12 December 2020

Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer

1 reference

12 December 2020

Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer

1 reference

12 December 2020

Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases

1 reference

12 December 2020

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

12 December 2020

Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy

1 reference

12 December 2020

High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer

1 reference

12 December 2020

Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer?

1 reference

12 December 2020

10.1007/S00066-012-0081-8

Identifiers

DOI

1 reference

23 November 2017

1 reference